NICE Approves Eylea For myopic chorodial neovascularization (mCNV) Patients In The UK

NICE Approves Eylea For myopic chorodial neovascularization (mCNV) Patients In The UK

UK patients suffering from myopic chorodial neovascularization (mCNV) will soon have a brand new treatment method at their disposal. The National Institute of Health and Care Excellence (NICE) has just approved Eylea eye injections for anyone suffering from mCNV.

Scientists at Regeneron Pharmaceuticals are behind these revolutionary Eylea injections. In medical jargon, Eylea injections are known as anti-vascular endothelial growth factors (anti-VEGFs). VEGFs refer to natural proteins in a person's eyes. People with macular issues often have an overgrowth in their VEGFs, which eventually leak fluid into the eyes and create a whole host of problems.

Lars Bruening, the current CEO at Bayer UK and Ireland, said he was glad to hear NICE approved Eylea for mCNV patients. He went on to say, "It is great news for patients with mCNV in England and Wales who will have access to this effective treatment as soon as it is adopted by policy makers."

Ophthalmologists estimate that around 3 percent of the global population has some form of pathological myopia. Out of this 3 percent, between 5 to 10 percent of people get mCNV. Unfortunately, 90 percent of people who get mCNV are legally blind five years after they are diagnosed.

Doctors in the UK have already been using Eylea injections for conditions like age-related macular degeneration (AMD) and various forms of macular edema. The Food and Drugs Administration (FDA) in the USA has also approved Eylea for use on conditions like wet AMD, macular edema after a retinal vein occlusion, and diabetic macular edema.

To help patients better understand whether or not Eylea might be a good option for them, Regeneron created a free app called In My Eyes. This app shows people what it's like to live with different retinal diseases and the exact conditions Eylea injections can treat. You can download this free app onto any Apple or Android product.

Regeneron is an American multinational biotech company based in Tarrytown, NY. There are a few Regeneron offices in the UK and Ireland for anyone interested in contacting them directly. Regeneron's London office is at 11-12 St. James's Square, and the company's two Irish offices are in Dublin and Limerick.

Anyone interested in learning more about Eylea can call Regeneron's hotline at 1-855-395-3248 or send the company an email on this website. The company also has social media pages on Facebook and Twitter.

« Back to list